Akèy › Kansè Poumon ki pa ti selil › Kentucky
Etid klinik pou Kansè Poumon ki pa ti selil nan Kentucky
46 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Kentucky.
Vil nan Kentucky
Tèks ofisyèl etid la (Anglè)
A Study of ZW251 in Participants With Advanced Solid Tumors
- Norton Cancer Institute, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07164313Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Owensboro Health Mitchell Memorial Cancer Center, Owensboro
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT07388524Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT06060613Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Baptist Health Corbin, Corbin
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT04267848A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0034, Lexington
- Local Institution - 0171, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07680764A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06780085A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- University of Kentucky Chandler Medical Center, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07361497A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Norton Cancer Institute Downtown, Louisville
- Norton Cancer Institute, Downtown, Louisville
- Norton Hospital, Louisville
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Lexington
- Research Site, Owensboro
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- Baptist Health Corbin, Corbin
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- ak 1 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Paducah
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06357533A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Saint Elizabeth Medical Center Edgewood, Edgewood
- Baptist Health Lexington, Lexington
- Local Institution - 0502, Paducah
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT06561386A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Saint Elizabeth Medical Center Edgewood, Edgewood
- The University of Louisville, James Graham Brown Cancer Center, Louisville
- Owensboro Medical Health System, Owensboro
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Baptist Health Hardin, Elizabethtown
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Lexington
- Research Site, Louisville
- Research Site, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Lexington Medical Cancer Center Hematology/Oncology, Lexington
- University of Louisville, Louisville
- Local Institution - 007-388-A, Louisville
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Markey Cancer Center, Lexington
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04486833Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Baptist Health Lexington /ID# 261823, Lexington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06236438FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Norton Cancer Institute Research, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06303505Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Norton Cancer Institute PARENT, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06750185A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Louisville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07291037A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- St. Elizabeth Healthcare, Edgewood
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06774963A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- University of Kentucky ( Site 0019), Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT06731907Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- University of Kentucky Chandler Medical Center, Lexington
- Norton Cancer Institute, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05142189Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Louisville, Louisville
Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jun 26, 2026 · NCT04614103Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05005403Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- UK Markey Cancer Center, Lexington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05283330A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Louisville, Louisville
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Jun 11, 2026 · NCT05361174Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Research Site, Louisville
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou May 14, 2026 · NCT06417814Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- University of Kentucky/Markey Cancer Center, Lexington
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
- Baptist Health Hardin, Elizabethtown
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 24, 2026 · NCT06841055Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.